HealthEquity (NASDAQ:HQY) Price Target Raised to $107.00 at JMP Securities

HealthEquity (NASDAQ:HQY) had its target price increased by JMP Securities from $105.00 to $107.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a market outperform rating on the stock.

HQY has been the subject of several other reports. Bank of America boosted their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada increased their target price on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their price target on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. The Goldman Sachs Group initiated coverage on shares of HealthEquity in a report on Friday, November 15th. They set a “neutral” rating and a $108.00 price objective on the stock. Finally, BTIG Research boosted their target price on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.71.

HealthEquity Price Performance

HealthEquity stock opened at $95.39 on Tuesday. The firm’s 50-day moving average is $93.11 and its two-hundred day moving average is $83.90. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The stock has a market capitalization of $8.33 billion, a P/E ratio of 79.49, a P/E/G ratio of 1.57 and a beta of 0.55. HealthEquity has a 12-month low of $62.10 and a 12-month high of $105.82.

Insider Buying and Selling

In other news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Frank Corvino sold 1,247 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the completion of the transaction, the director now owns 4,823 shares of the company’s stock, valued at $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,536 shares of company stock valued at $884,517. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

A number of institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP increased its position in shares of HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after acquiring an additional 483,269 shares during the last quarter. Mackenzie Financial Corp grew its stake in HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after purchasing an additional 325,906 shares in the last quarter. Generate Investment Management Ltd purchased a new stake in HealthEquity during the 2nd quarter worth approximately $24,184,000. Vaughan Nelson Investment Management L.P. raised its position in shares of HealthEquity by 36.7% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after purchasing an additional 226,563 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of HealthEquity by 924.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock valued at $18,983,000 after buying an additional 198,718 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.